BNR Burning Rock Biotech Ltd: Earnings per share for the last twelve months

Public company logo of Burning Rock Biotech Ltd. (BNR)

Serving as a valuation tool, the EPS (TTM) chart for Burning Rock Biotech (BNR) shows a figure of 51.40. The business relies on the implementation of liquid biopsy in medical centers for rapid tumor diagnostics. Meanwhile, management faces pressure from local laws and PRC risks, despite their digital literacy. Simultaneously, Burning Rock Biotech (BNR) is maximizing its development in NGS sequencing for the ultra-early detection of pathologies.

Burning Rock (BNR): Earnings per share for the last twelve months from 02/11/2024 to 11/17/2026

BNR (brbiotech.com): analytical breakdowns and indicator data

- current quotes and average value forecast:
Fundamental company valuation:Burning Rock Biotech Ltd. - BNR
Original product of Burning Rock Biotech

The implementation of Burning Rock Biotech (BNR) liquid biopsy standards across Chinese oncology clinics directly impacts earnings per share dynamics. By analyzing EPS YoY volatility over the last 12 months, investors can assess net profit growth rates on a rolling basis, which helps determine the business's margin of safety under negative scenarios and avoid purchasing the asset at local peaks.